ArticleInfection2025
Risk factors for 30-Day mortality and the role of empirical therapy in Pseudomonas aeruginosa bloodstream infections.
Article in Infection, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Predictors of Mortality inPathogens (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeP. aeruginosa bloodstream infections (BSIs) represent one of the most common conditions associated with increased healthcare costs, prolonged hospitalization and high attributable mortality. The primary objective of our study was to investigate all-cause 30-day mortality associated with P. aeruginosa BSIs.
methodsWe conducted a multicenter, retrospective cohort study in 14 Italian hospitals, including all consecutive patients with P. aeruginosa BSIs from January 2021 to December 2022. We included all patients who were ≥ 18 years old with P. aeruginosa BSIs treated for at least 48 h with an anti-Pseudomonal antibiotic regimen that was sensitive in vitro.
resultsSix hundred and thirty-nine P. aeruginosa BSIs were collected from participating centers. After applying the exclusion criteria, 511 BSIs remain. The median age was 68.0 (IQR 57.0–77.0). Three hundred and forty (66.5%) patients were male. One hundred eight (21.1%) patients experienced in-hospital 30-day mortality. Most BSIs were caused by susceptible strains of P. aeruginosa (474 isolates, 92.8%). At the multivariate logistic regression analysis, older age [1.03 (1.01–1.05), p = 0.003], presence of sepsis [OR 2.75 (1.43–5.27), p = 0.002], presence of septic shock [6.53 (3.33–12.80), p < 0.001] and high-risk infections [OR 2.74 (1.36–5.49), p = 0.005] were associated with the worst outcome. The combination of empirical therapy [OR 0.39 (0.16–0.96), p = 0.04] was the only variable associated with improved survival.
conclusionAppropriate empirical therapy with two in vitro active molecules was beneficial in terms of all-cause 30-day mortality, especially in patients with severe clinical presentations, such as septic shock and high-risk infections.
Indexed as
Identifiers
40719964What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.